Stockscreener 앱 받기
1.43
7.74%
-0.12
시장 영업 전:
1.43
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataAlgorithmic Prediction of Market Breakouts - Newser
What indicators show strength in Inhibikase Therapeutics Inc.Free Real Market Momentum Signal Generator - Newser
Automated trading signals detected on Inhibikase Therapeutics Inc.Free Momentum Based Equity Trading Plan - Newser
Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Entry Confirmation Using Short-Term Forecasting - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceReversal Pattern Insights with Entry Tips - Newser
Chart based analysis of Inhibikase Therapeutics Inc. trendsDaily Entry Opportunity Forecasting Tool - Newser
How high can Inhibikase Therapeutics Inc. stock goMonthly Long-Term Market Recap and Summary - Newser
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Tactical Trade Setup With Entry Optimizer - Newser
Using fundamentals and technicals on Inhibikase Therapeutics Inc.Top Stock Picks with Forecast Accuracy - Newser
What risks could impact Inhibikase Therapeutics Inc. stock performanceFree Weekly Potential Breakout Stock List - Newser
Inhibikase Therapeutics Inc. recovery potential after sell offSmart Risk Strategy with Entry Optimization - Newser
How Inhibikase Therapeutics Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser
Real time pattern detection on Inhibikase Therapeutics Inc. stockChart Driven Opportunity Scanner with Alerts - Newser
Published on: 2025-08-06 00:58:01 - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockPortfolio Allocation Strategy for Stability - Newser
Published on: 2025-08-04 16:30:58 - metal.it
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free AI Driven Buy Alert Trade Blueprint - Newser
What institutional investors are buying Inhibikase Therapeutics Inc. stockMarket-leading capital gains - Jammu Links News
How does Inhibikase Therapeutics Inc. compare to its industry peersOutstanding capital growth - Jammu Links News
Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedFastest return on investment - Jammu Links News
What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News
When is Inhibikase Therapeutics Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - Jammu Links News
What are the latest earnings results for Inhibikase Therapeutics Inc.Unlock powerful investment tools for free - Jammu Links News
Is it the right time to buy Inhibikase Therapeutics Inc. stockDiscover market opportunities with expert help - Jammu Links News
Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Early Breakout Entry Point Notifications - newser.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News
What drives Inhibikase Therapeutics Inc. stock priceMaximize gains with data-driven trading alerts - Jammu Links News
What are Inhibikase Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News
Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Comparison - Defense World
Published on: 2025-08-01 22:50:53 - Newser
Intraday pattern recognizer results for Inhibikase Therapeutics Inc.ROI Focused Watchlist with Trade Confidence - Newser
0.24%
3.39%
자본화:
|
볼륨(24시간):